Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
Atopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for A...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/11/2452 |
| _version_ | 1797464246852780032 |
|---|---|
| author | Yuliya Lytvyn Asfandyar Mufti Abrahim Abduelmula Muskaan Sachdeva Khalad Maliyar Jorge R. Georgakopoulos Jensen Yeung |
| author_facet | Yuliya Lytvyn Asfandyar Mufti Abrahim Abduelmula Muskaan Sachdeva Khalad Maliyar Jorge R. Georgakopoulos Jensen Yeung |
| author_sort | Yuliya Lytvyn |
| collection | DOAJ |
| description | Atopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for AD, there remains a large need for effective and safe alternative therapies for long-term use. Janus kinase (JAK) inhibitors are a new class of agents that target the JAK-STAT pathway, which plays an important role in the production of proinflammatory cytokines involved in AD pathogenesis. Phase II and III clinical trials revealed that JAK inhibitors, such as upadacitinib, are effective and well-tolerated agents for the treatment of moderate-to-severe AD. As a result, upadacitinib was approved for use in patients with moderate-to-severe AD by the European Medicines Agency (2021), Health Canada (2021) and the FDA (2022) in the last year. It is important for dermatologists to be aware of the clinical evidence to continue incorporating the use of upadacitinib into the treatment algorithm for AD, which will ultimately lead to improved patient outcomes. Therefore, this review is an up-to-date summary of the clinical data available on the efficacy and safety of upadacitinib treatment for AD. |
| first_indexed | 2024-03-09T18:04:52Z |
| format | Article |
| id | doaj.art-c741dffc7b64416aa66cb4e444c0ecdc |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T18:04:52Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-c741dffc7b64416aa66cb4e444c0ecdc2023-11-24T09:36:04ZengMDPI AGPharmaceutics1999-49232022-11-011411245210.3390/pharmaceutics14112452Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based ReviewYuliya Lytvyn0Asfandyar Mufti1Abrahim Abduelmula2Muskaan Sachdeva3Khalad Maliyar4Jorge R. Georgakopoulos5Jensen Yeung6Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaFaculty of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, CanadaDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaAtopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for AD, there remains a large need for effective and safe alternative therapies for long-term use. Janus kinase (JAK) inhibitors are a new class of agents that target the JAK-STAT pathway, which plays an important role in the production of proinflammatory cytokines involved in AD pathogenesis. Phase II and III clinical trials revealed that JAK inhibitors, such as upadacitinib, are effective and well-tolerated agents for the treatment of moderate-to-severe AD. As a result, upadacitinib was approved for use in patients with moderate-to-severe AD by the European Medicines Agency (2021), Health Canada (2021) and the FDA (2022) in the last year. It is important for dermatologists to be aware of the clinical evidence to continue incorporating the use of upadacitinib into the treatment algorithm for AD, which will ultimately lead to improved patient outcomes. Therefore, this review is an up-to-date summary of the clinical data available on the efficacy and safety of upadacitinib treatment for AD.https://www.mdpi.com/1999-4923/14/11/2452atopic dermatitiseczemaupadacitinibJAK1 inhibitors |
| spellingShingle | Yuliya Lytvyn Asfandyar Mufti Abrahim Abduelmula Muskaan Sachdeva Khalad Maliyar Jorge R. Georgakopoulos Jensen Yeung Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review Pharmaceutics atopic dermatitis eczema upadacitinib JAK1 inhibitors |
| title | Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review |
| title_full | Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review |
| title_fullStr | Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review |
| title_full_unstemmed | Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review |
| title_short | Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review |
| title_sort | efficacy and safety of upadacitinib for management of moderate to severe atopic dermatitis an evidence based review |
| topic | atopic dermatitis eczema upadacitinib JAK1 inhibitors |
| url | https://www.mdpi.com/1999-4923/14/11/2452 |
| work_keys_str_mv | AT yuliyalytvyn efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT asfandyarmufti efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT abrahimabduelmula efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT muskaansachdeva efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT khaladmaliyar efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT jorgergeorgakopoulos efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview AT jensenyeung efficacyandsafetyofupadacitinibformanagementofmoderatetosevereatopicdermatitisanevidencebasedreview |